The global Human Immunodeficiency Virus (HIV) diagnosis and treatment market is expected to grow at a CAGR of 7.6 % during 2017-2022. The HIV impact on the immune system of human body and weakens the individual defense system against any infections. It attacks & destroys a type of white blood cell, T-helper cell and replicates. Its produces have several copies of itself inside these white blood cells. Progressively the immune system becomes weak to any kind of infections. This condition and situation is known as acquired deficiency syndrome (AIDS). According to world health organization (WHO), it is a main global public health issue. In 2015, 1.2 million people died with HIV related infections across the globe and approximately 36.8 million people are currently suffering from HIV. As a result, the global HIV diagnosis and treatment market is rapidly growing, and continuously working on trials for the proper diagnosis followed by treatment. The market for HIV is growing at the pace, and also the increasing occurrence of HIV/AIDS infection globally boosting is the market, also government taking initiatives diagnosis and treatment and increasing in blood donations and blood transfusions and increasing awareness about HIV/AIDS. One of the major reason for the increase in the number of HIV infection across the globe, includes, changing lifestyle, injection drug usage, and lack of awareness and unprotected sex in some region. A prime factor driving the market for HIV treatment market is government and Non-governmental organizations (NGOs) efforts to initiate against HIV/AIDS.
The HIV diagnosis and treatment market was segmented majorly on the basis of type, product, treatment, and end user. On the basis of type, the market is further segmented into antibody tests, viral identification assays, cd4 testing, viral load testing, and early infant diagnostics. Antibody tests have a largest market share in the diagnosis of AID. On the basis of product, HIV diagnosis and treatment market can be segmented into assays and kits & reagents, instruments and software & service. In product segment, the product assays and kits is anticipated to lead the growth of the global HIV diagnosis and treatment market during the next few years. On the basis of treatment HIV diagnosis & treatment market can be segmented into protease inhibitors (PIS), non-nucleoside reverse transcriptase inhibitors (NNRTIS), nucleoside or nucleotide reverse transcriptase inhibitors (NRTIS), entry or fusion inhibitors, integrase inhibitors and others. In the treatment segment, the protease inhibitors (PIS) are the main treatment for the t global HIV treatment market.
Geographical insights
North America and Europe are the leading the market of the global HIV diagnosis and treatment market having strong healthcare R&D scenario. Regional government is taking initiatives for the ongoing diagnostic efforts for development of new treatment and products. Asia Pacific is anticipated to grow at the high pace due to many issues regarding screening and testing of HIV. Furthermore, partnerships among the western market players and the governments in the region are another major aspect fueling the growth of HIV diagnosis and treatment market.
Competitive insights
The main players functioning in the global HIV diagnosis and treatment market include Siemens Healthcare, Abbott Laboratories, Roche molecular systems Inc., Bio-Rad laboratories, QIAGEN, Danaher Corporation, Becton, Dickinson and company, Merck KGAA, Biomerieux SA, Medmira Inc., Hologic Inc., Alere Inc., and others. In 2015, the U.S. food and drug administration (FDA) has approved the Siemens ADVIA Centaur HIV Ag/Ab combo (CHIV) assay.
Market segmentation
The report covers
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
3. MARKET DETERMINANT
3.1. MARKET MOTIVATORS
3.1.1. FAVOURABLY REGULATORY LANDSCAPE
3.1.2. POC HIV DIAGNOSTICS DEVELOPMENT
3.1.3. DEVELOPMENT OF SINGLE BLOOD DROP ANALYSER FOR HIV TEST
3.1.4. INCREASING HIV/AIDS PREVALENCE
3.1.5. INCREASING NUMBER OF BLOOD TRANSFUSIONS AND BLOOD DONATIONS
3.1.6. INCREASING GOVERNMENT INITIATIVES
3.2. RESTRAINT
3.2.1. LOW DEGREE OF PENETRATION IN UNDEVELOPED REGIONAL MARKETS
3.2.2. STRINGENT REGULATORY REQUIREMENTS FOR THE APPROVAL AND COMMERCIALIZATION OF NEW DRUGS AND THERAPY
3.3. OPPORTUNITY
3.3.1. RISE IN NUMBER OF HIV INFECTION ACROSS THE GLOBE.
3.3.2. INCREASE IN TECHNOLOGY ADVANCEMENT FOR THE DIAGNOSIS AND TREATMENT FOR THE HIV
4. MARKET SEGMENTATION
4.1. HIV DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY TEST TYPE
4.1.1. ANTIBODY TESTS
4.1.1.1. HIV-1 SCREENING TESTS
4.1.1.2. HIV-1 ANTIBODY CONFIRMATORY TESTS
4.1.1.3. HIV-2 & GROUP O DIAGNOSTIC TESTS
4.1.2. VIRAL IDENTIFICATION ASSAYS
4.1.3. CD4 TESTING
4.1.4. VIRAL LOAD TESTING
4.1.5. EARLY INFANT DIAGNOSTICS
4.2. HIV DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC PRODUCT
4.2.1. ASSAYS, KITS & REAGENTS
4.2.2. INSTRUMENTS
4.2.3. SOFTWARE & SERVICE
4.2.4. OTHERS (POC AND SINGLE BLOOD DROP ANALYSER)
4.3. HIV DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS, BY TREATMENT.
4.3.1. PROTEASE INHIBITORS (PIS)
4.3.2. NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)
4.3.3. NUCLEOSIDE OR NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)
4.3.4. ENTRY OR FUSION INHIBITORS
4.3.5. INTEGRASE INHIBITORS
4.3.6. OTHERS
4.4. HIV DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS, BY USER
4.4.1. DIAGNOSTIC LABORATORIES
4.4.2. HOSPITALS
4.4.3. BLOOD BANKS
4.4.4. HOME CARE SETTINGS
4.4.5. OTHER END USERS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPEAN MARKET RESEARCH AND ANALYSIS
6.2.1. UK
6.2.2. GERMANY
6.2.3. SPAIN
6.2.4. FRANCE
6.2.5. ITALY
6.2.6. ROE
6.3. ASIA-PACIFIC MARKET RESEARCH AND ANALYSIS
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS
7. COMPANY PROFILES (Company Overview, Product Portfolio, Recent developments, Revenue Analysis)
7.1. ABBOTT LABORATORIES
7.2. BOEHRINGER INGELHEIM GMBH
7.3. BRISTOL-MYERS SQUIBB COMPANY
7.4. CIPLA INC.
7.5. F. HOFFMANN-LA ROCHE LTD
7.6. GILEAD
7.7. GLAXOSMITHKLINE PLC.
7.8. HOLOGIC INC.
7.9. INC.(US), VIIV HEALTHCARE GROUP OF COMPANIES
7.10. JANSSEN DIAGNOSTICS
7.11. JOHNSON & JOHNSON SERVICES
7.12. MERCK & CO. INC.
7.13. MYLAN INC.
7.14. PARTEC
7.15. POINTCARE TECHNOLOGIES INC.
7.16. QIAGEN
7.17. ROCHE DIAGNOSTICS
7.18. SIEMENS HEALTHCARE
7.19. SYSMEX CORPORATION
7.20. ZYOMYX INC.
TABLE # 1 GLOBAL HIV DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY TEST TYPE 2016-2022 ($ MILLION)
TABLE # 2 GLOBAL ANTIBODY TESTS MARKETRESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 3 GLOBAL HIV-1 SCREENING TESTSMARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 4 GLOBAL HIV-1ANTIBODY CONFIRMATORY TESTS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 5 GLOBAL HIV-2 & GROUP O DIAGNOSTIC TESTS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 6 GLOBAL VIRAL IDENTIFICATION ASSAYSMARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 7 GLOBAL CD4 TESTING MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 8 GLOBAL VIRAL LOAD TESTING MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 9 GLOBAL EARLY INFANT DIAGNOSTICSMARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 10 GLOBAL HIV DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT 2016-2022 ($ MILLION)
TABLE # 11 GLOBAL ASSAYS AND KITS & REAGENTSMARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 12 GLOBAL INSTRUMENTS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 13 GLOBAL SOFTWARE & SERVICE MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 14 GLOBAL HIV DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT 2016-2022 ($ MILLION)
TABLE # 15 GLOBAL PIS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 16 GLOBAL NNRTIS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 17 GLOBAL NRTIS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 18 GLOBAL ENTRY OR FUSION INHIBITORS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 19 GLOBAL INTEGRASE INHIBITORS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 20 GLOBAL HIV DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY USER 2016-2022 ($ MILLION)
TABLE # 21 GLOBAL DIAGNOSTIC LABORATORIES MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 22 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 23 GLOBAL BLOOD BANKS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 24 GLOBAL HOME CARE SETTINGS MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
TABLE # 25 GLOBAL HIV DIAGNOSIS & TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2016-2022 ($ MILLION)
TABLE # 26 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, BY COUNTRY 2016-2022 ($ MILLION)
TABLE # 27 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, BY TEST TYPE 2016-2022 ($ MILLION)
TABLE # 28 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC PRODUCT 2016-2022 ($ MILLION)
TABLE # 29 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2016-2022 ($ MILLION)
TABLE # 30 EUROPEAN MARKET RESEARCH AND ANALYSIS, BY COUNTRY 2016-2022 ($ MILLION)
TABLE # 31 EUROPEAN MARKET RESEARCH AND ANALYSIS, BY TEST TYPE 2016-2022 ($ MILLION)
TABLE # 32 EUROPEAN MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC PRODUCT 2016-2022 ($ MILLION)
TABLE # 33 EUROPEAN MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2016-2022 ($ MILLION)
TABLE # 34 APAC MARKET RESEARCH AND ANALYSIS BY COUNTRY 2016-2022, ($ MILLION)
TABLE # 35 APAC MARKET RESEARCH AND ANALYSIS BY TEST TYPE 2016-2022, ($ MILLION)
TABLE # 36 APAC MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC PRODUCT 2016-2022, ($ MILLION)
TABLE # 37 APAC MARKET RESEARCH AND ANALYSIS BY TREATMENT 2016-2022, ($ MILLION)
TABLE # 38 ROW MARKET RESEARCH AND ANALYSIS BY TEST TYPE 2016-2022 ($ MILLION)
TABLE # 39 ROW MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC PRODUCT 2016-2022 ($ MILLION)
TABLE # 40 ROW MARKET RESEARCH AND ANALYSIS BY TREATMENT 2016-2022 ($ MILLION)
FIGURE # 1 GLOBAL HIV DIAGNOSIS & TREATMENT MARKET SHARE BY TEST TYPE 2016 AND 2022 (%)
FIGURE # 2 GLOBAL HIV DIAGNOSIS & TREATMENT MARKET SHARE BY PRODUCT 2016 AND 2022 (%)
FIGURE # 3 GLOBAL HIV DIAGNOSIS & TREATMENT MARKET SHARE BY TREATMENT 2016 AND 2022 (%)
FIGURE # 4 GLOBAL HIV DIAGNOSIS & TREATMENT MARKET SHARE BY GEOGRAPHY 2016-2022 (%)
FIGURE # 5 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 6 UNITED STATES MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 7 CANADA MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 8 EUROPEAN MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 9 UK MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 10 GERMANY MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 11 SPAIN MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 12 FRANCE MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 13 ITALY MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 14 ROE MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 15 APAC MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 16 INDIA MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 17 CHINA MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 18 JAPAN MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 19 ROAPAC MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)
FIGURE # 20 ROW MARKET RESEARCH AND ANALYSIS 2016-2022 ($ MILLION)